FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.
Br J Cancer
; 104(7): 1079-84, 2011 Mar 29.
Article
in En
| MEDLINE
| ID: mdl-21386839
ABSTRACT
BACKGROUND:
In patients with colorectal liver metastases (CLM) R0 resection significantly improves overall survival (OS).METHODS:
In this report, we present the results of a phase II trial of FOLFOX6+bevacizumab in patients with non-optimally resectable CLM. Patients received six cycles of FOLFOX6+ five of bevacizumab. Patients not achieving resectability received six additional cycles of each. A PET-CT was performed at baseline and again within 1 month after initiating treatment.RESULTS:
From September 2005 to July 2009, 21 patients were enrolled (Male/Female 15/6; median age 65 years). An objective response (OR) was documented in 12 cases (57.1%; complete responses (CRs) 3, partial response (PR) 9); one patient died from toxicity before surgery. Thirteen patients underwent radical surgery (61.9%). Three (23%) had a pathological CR (pCR). Six patients (46.1%) experienced minor postsurgical complications. After a median 38.8-month follow-up, the median OS was 22.5 months. Patients achieving at least 1 unit reduction in Standard uptake value (SUV)max on PET-CT had longer progression-free survival (PFS) (median PFS 22 vs 14 months, P=0.001).CONCLUSIONS:
FOLFOX6+bevacizumab does not increase postsurgical complications, yields high rates of resectability and pCR. Early changes in PET-CT seem to be predictive of longer PFS.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Colorectal Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Liver Neoplasms
/
Antibodies, Monoclonal
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Br J Cancer
Year:
2011
Type:
Article
Affiliation country:
Italy